Concepedia

Rémy Gébleux

RG

Statistics

Publications

11

Citations

639

H-Index

10

Active since

2015

Affiliations

ETH Zurich(Current)

NBE Therapeutics (Switzerland)

University of Basel

University Hospital of Zurich

Philochem (Switzerland)

Rémy Gébleux is an author at ETH Zurich specializing in antibody-drug conjugates, antibody conjugates, and pharmacology.

Publications per year

2015–2021

11

Publications

11

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Lucia D’Amico, Ulrike Menzel, Michael Prummer et al. · Journal for ImmunoTherapy of Cancer · 2019 · 128 citations · Full text

, , +17

Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

Rémy Gébleux, Marco Stringhini, Ruben Casanova et al. · International Journal of Cancer · 2016 · 117 citations · Full text

, , +17

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody–Drug Conjugates

Alberto Dal Corso, Samuele Cazzamalli, Rémy Gébleux et al. · Bioconjugate Chemistry · 2017 · 85 citations · Full text

, , +17

Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

Nikolas Stefan, Rémy Gébleux, Lorenz Waldmeier et al. · Molecular Cancer Therapeutics · 2017 · 77 citations · Full text

, , +17

A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo

Alberto Dal Corso, Rémy Gébleux, Patrizia Murer et al. · Journal of Controlled Release · 2017 · 74 citations · Full text

, , +12

1–5 of 11